STAMFORD, Conn., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Joseph Stauffer, Chief Medical Officer, will present previously announced results from the Phase 2b trial of Oral CR845 in patients with osteoarthritis of the knee or hip at the Janney Montgomery Scott Osteoarthritis Pain Conference on Wednesday, October 11, 2017, at 11:15 a.m. ET in New York.
To access a live webcast of the presentation, follow the link below:
https://cc.callinfo.com/registration/#/?meeting=1bz6od0w77fq9&campaign=12mx4sd7oz45k
An audio recording of the presentation will be available by telephone:
- U.S. & Canada Toll-Free Dial-In: 1-877-256-3251
- U.K. Dial-In: +44 080-0692-2011
- Local Toll-Free Dial-In: 1-212-231-2921
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates, led by CR845, that target the body's peripheral nervous system. CR845 has demonstrated initial efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available pain therapeutics. In patients with moderate-to-severe CKD-associated pruritus, CR845 has demonstrated its potential to reduce itch and improve quality of life.
INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
michael@sternir.com
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com